510(k) vs. De Novo: Key Differences in FDA Approval Pathways for Medical Devices

The U.S. medical device market is one of the most highly regulated in the world. For manufacturers aiming to launch their products, selecting the right FDA approval pathway is critical to avoid costly delays and ensure compliance. For non–PMA (Premarket Approval) devices, two primary options are available: the 510(k) Premarket Notification and the De Novo Classification Request.

Although both routes allow medical devices to reach the U.S. market, they differ significantly in terms of eligibility, timelines, evidence requirements, and long-term business impact. Let’s break down the key differences between 510(k) vs. De Novo to help you choose the most suitable pathway.

Understanding the 510(k) Pathway

The 510(k) submission is the most common FDA clearance process. It is applicable when a device can be shown to be substantially equivalent to a device already legally marketed in the United States (a predicate device).

To qualify under 510(k):

• The intended use must be the same as the predicate device.
• The technology must be similar, or any differences must not raise new safety or performance issues.

Once the FDA confirms substantial equivalence, it issues a Substantially Equivalent (SE) Letter, formally clearing the product for U.S. commercialization.

Average timeline: about 90 calendar days.

This pathway is often preferred for its speed and cost-effectiveness, making it ideal for devices with existing comparables.

Understanding the De Novo Pathway

The De Novo process is designed for novel devices that do not have a suitable predicate but are considered low to moderate risk. These devices fall outside the scope of 510(k) but do not require the more rigorous PMA pathway.

When granted, the FDA issues a De Novo Grant Order, which:

• Authorizes the device for U.S. market entry.
• Creates a new product classification under 21 CFR.
• Assigns a unique product code.
• May establish special controls specific to that device type.

Beyond market authorization, De Novo provides a strategic advantage by setting a regulatory standard for similar devices in the future.

510(k) vs. De Novo: Side-by-Side Comparison

The deciding factor between these two FDA pathways is the existence of a predicate device.

Factor510(k) PathwayDe Novo PathwayPredicate DeviceRequiredNot requiredDevice RiskLow to moderateLow to moderate (novel devices)Review Speed~90 daysTypically longerStrategic ValueFaster, less costlyDefines a new classification

Manufacturers can approach De Novo in two ways:

1. Post-NSE De Novo: Submitted after a failed 510(k), where the FDA deems the device Not Substantially Equivalent (NSE).
2. Direct De Novo: Filed directly if no predicate exists.

While 510(k) is faster, the De Novo pathway offers long-term positioning benefits, particularly for innovative devices like AI-driven technologies or first-of-its-kind solutions.

Post-Market Compliance Obligations

Whether cleared through 510(k) or authorized via De Novo, manufacturers must comply with FDA post-market requirements, including:

• Quality System Regulation (21 CFR Part 820): Covering design, production, and quality assurance.
• Medical Device Reporting (21 CFR Part 803): Monitoring and reporting adverse events.
• Unique Device Identification (UDI): Labeling and traceability requirements.
• Special Controls (for De Novo): Device-specific rules defined during the grant.

Non-compliance can lead to enforcement actions, recalls, or loss of market authorization.

How to Choose the Right FDA Pathway

The choice between 510(k) vs. De Novo should be based on:

• Availability of a predicate device.
• Device risk profile.
• Long-term commercial and regulatory strategy.

Making the right decision early saves time, reduces regulatory risk, and ensures faster access to the U.S. market.

Final Thoughts

The 510(k) pathway is best suited for devices with an existing predicate, offering faster review and lower costs. In contrast, the De Novo pathway is essential for innovative, low to moderate risk devices that lack a predicate but need formal FDA authorization and classification.

To explore a more detailed comparison, visit the full article on Freyr Solutions: 510(k) vs. De Novo – Key Differences in FDA Approval Pathways for Medical Devices.

At Freyr Solutions, our regulatory experts support medical device companies in preparing FDA submissions, defining strategy, and meeting compliance requirements. Whether you are pursuing a 510(k) clearance or a De Novo submission, we ensure a smoother and more efficient approval process.

👉 Reach out today to get expert guidance for your FDA regulatory pathway.